Format

Send to

Choose Destination
Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816.

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.

Author information

1
OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A.
2
Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A.
3
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, U.S.A.
4
The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Abstract

Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) - the lethal form of the disease that has progressed despite therapies that interfere with activation of androgen receptor (AR) signaling. One emergent resistance mechanism to medical castration is synthesis of intratumoral androgens that activate the AR. This insight led to the development of the AR antagonist enzalutamide. However, resistance to enzalutamide invariably develops, and disease progression is nearly universal. One mechanism of resistance to enzalutamide is an F877L mutation in the AR ligand-binding domain that can convert enzalutamide to an agonist of AR activity. However, mechanisms that contribute to the agonist switch had not been fully clarified, and there were no therapies to block AR F877L. Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR. Further, enzalutamide treatment of AR F877L-expressing cell lines recapitulated the effects of androgen activation of F877L AR or wild-type AR. Because the BET bromodomain inhibitor JQ-1 was previously shown to block androgen activation of wild-type AR, we tested JQ-1 in AR F877L-expressing CRPC models. We determined that JQ-1 suppressed androgen or enzalutamide activation of mutant F877L AR and suppressed growth of mutant F877L AR CRPC tumors in vivo, demonstrating a new strategy to treat tumors harboring this mutation.

KEYWORDS:

BET bromodomain inhibition; androgen receptor mutations; genitourinary cancers: prostate; hormone signaling and inhibitors; regulation of gene expression in drug resistance

PMID:
27276681
PMCID:
PMC5130036
DOI:
10.18632/oncotarget.9816
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center